Immunotherapy of malignant melanoma.
The growth of melanoma in humans depends not only on the malignant potential of the tumor but also on the patient's immune response to the melanoma. As a result, a variety of strategies have evolved to treat melanoma by stimulating antitumor immune responses to melanoma. This article reviews the different approaches being taken and the results obtained to date.
Oratz
R
R
Kaplan Cancer Center, New York University School of Medicine, New York.
Bystryn
J C
JC
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D016219:Immunotherapy, Adoptive; D007372:Interferons / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*; D014611:Vaccination
D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D007372:Interferons